Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan.
Department of Small Animal Internal Medicine, School of Veterinary Medicine, University of Kitasato, Towada, Aomori 034-8628, Japan.
Int J Mol Sci. 2018 Jan 17;19(1):282. doi: 10.3390/ijms19010282.
We prepared magnesium hydroxide (MH) nanoparticles, and investigated their effect when combined with dissolved carteolol on the bioavailability and intraocular pressure (IOP)-reducing effect of carteolol. The carteolol was solved in saline containing additives (0.5% methylcellulose, 0.001% benzalkonium chloride, 0.5% mannitol; CRT-solution). MH nanoparticles were prepared by a bead mill method with additives. Then carteolol/MH microparticle and carteolol/MH nanoparticle fixed combinations (mCMFC and nCMFC) were prepared by mixing the CRT-solution and MH particles. The transcorneal penetration and IOP-reducing effect of carteolol was evaluated in rabbits. The mean particle size of mCMFC was 7.2 μm, and the particle size was reduced to 73.5-113.5 nm by the bead mill treatment. The MH particles in nCMFC remained in the nano size range for 8 days after preparation, and the amounts of lacrimal fluid and corneal damage were unchanged by repetitive instillation of nCMFC (twice a day for 4 weeks). The transcorneal penetration of carteolol was enhanced by the combination with MH nanoparticles, and the IOP-reducing effect of nCMFC was significantly higher than that of CRT-solution or mCMFC. In conclusion, we designed nCMFC, and showed that the high levels of dissolved carteolol can be delivered into the aqueous humor by the instillation of nCMFC. Combination with MH nanoparticles may achieve an enhancement of corneal penetration for water-soluble drugs. These findings provide significant information that can be used to design further studies aimed at developing anti-glaucoma eye drugs.
我们制备了氢氧化镁 (MH) 纳米粒子,并研究了其与溶解的卡替洛尔联合使用对卡替洛尔生物利用度和降眼压 (IOP) 效果的影响。卡替洛尔溶解在含有添加剂的盐水中(0.5%甲基纤维素、0.001%苯扎氯铵、0.5%甘露醇;CRT 溶液)。MH 纳米粒子通过添加物的珠磨机方法制备。然后通过混合 CRT 溶液和 MH 颗粒来制备卡替洛尔/MH 微颗粒和卡替洛尔/MH 纳米颗粒固定组合(mCMFC 和 nCMFC)。在兔子中评估了卡替洛尔的经角膜穿透和降眼压效果。mCMFC 的平均粒径为 7.2 μm,通过珠磨机处理粒径减小至 73.5-113.5 nm。nCMFC 中的 MH 颗粒在制备后 8 天内仍保持纳米尺寸范围,并且通过重复滴注 nCMFC(每天两次,持续 4 周)不会改变泪液量和角膜损伤。卡替洛尔与 MH 纳米粒子的组合增强了经角膜穿透,nCMFC 的降眼压效果明显高于 CRT 溶液或 mCMFC。总之,我们设计了 nCMFC,并表明通过滴注 nCMFC 可以将高浓度溶解的卡替洛尔递送至房水中。与 MH 纳米粒子的组合可能会增强水溶性药物的角膜穿透。这些发现提供了有意义的信息,可用于设计旨在开发抗青光眼眼用药物的进一步研究。